Sera Prognostics, Inc. (SERA): Cost of Revenue
$164.0K
Year ended 2025-12-31
$175.0K
Trailing 12 months to 2026-06-30
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $164.0K | +100.0% | 2026-03-18, From 2025-01-01 |
| 2024-12-31 | $82.0K | -61.0% | 2026-03-18, From 2024-01-01 |
| 2023-12-31 | $210.0K | n/a | 2025-03-19, From 2023-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Sera Prognostics, Inc. (SERA) | 2025-12-31 | $164.0K | +100.0% |
| Aclarion, Inc. (ACON) | 2025-12-31 | $68.9K | -18.6% |
| YD Bio Ltd (YDES) | 2025-12-31 | $429.4K | +21.0% |
| BioNexus Gene Lab Corp (BGLC) | 2025-12-31 | $6.34M | -22.9% |
| American Shared Hospital Services (AMS) | 2025-12-31 | $23.02M | +20.2% |
| Exagen Inc. (XGN) | 2025-12-31 | $27.78M | +23.3% |
| Personalis, Inc. (PSNL) | 2025-12-31 | $53.87M | -6.8% |
| BillionToOne, Inc. (BLLN) | 2025-12-31 | $96.65M | +34.9% |
| Fulgent Genetics, Inc. (FLGT) | 2025-12-31 | $191.80M | +8.8% |
Compare SERA, ACON, YDES, BGLC side by side · Screen every company in Services-Medical Laboratories ↗